Medically reviewed by Drugs.com. Last updated on Feb 17, 2022.
The recommended starting dosage is 300 mg administered subcutaneously every 2 weeks. A dosing interval of 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.
Preparation and Administration Instructions
TAKHZYRO is administered subcutaneously only.
TAKHZYRO is intended for self-administration or administration by a caregiver. The patient or caregiver should be trained by a healthcare professional.
TAKHZYRO is provided as a ready-to-use solution that does not require additional reconstitution or dilution for administration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. TAKHZYRO is a clear to slightly opalescent, colorless to slightly yellow solution.
Instructions for single-dose prefilled syringe
Do not use the prefilled syringe if the solution appears discolored or contains visible particles. Avoid vigorous agitation of the prefilled syringe.
Take the TAKHZYRO prefilled syringe out of the refrigerator 15 minutes before injecting to allow it to equilibrate to room temperature.
Using aseptic technique, inject TAKHZYRO subcutaneously into the abdomen, thigh, or upper arm. Patients should inject the complete dose as prescribed by their physician.
Discard any unused portion of drug remaining in the prefilled syringe.
For detailed instructions on the preparation and administration of TAKHZYRO see single-dose prefilled syringe Instructions for Use.
Instructions for single-dose vial
Do not use the vial if the solution appears discolored or contains visible particles. Avoid vigorous agitation of the vial.
Take the TAKHZYRO vial out of the refrigerator 15 minutes before injecting to allow it to equilibrate to room temperature.
Using aseptic technique, withdraw the prescribed dose of TAKHZYRO from the vial using an 18-gauge needle. Change the needle on the syringe to a 27-gauge, ½-inch needle or other needle suitable for subcutaneous injection. Inject TAKHZYRO subcutaneously into the abdomen, thigh, or upper arm. Patients should inject the complete dose as prescribed by their physician. In clinical studies, the majority of patients self-administered TAKHZYRO over 10 to 60 seconds.
TAKHZYRO should be administered within 2 hours of preparing the dosing syringe. After the dosing syringe is prepared, it can be refrigerated at 36ºF to 46ºF (2°C to 8°C) and must be used within 8 hours.
Discard any unused portions of drug remaining in the vial and dosing syringe.
For detailed instructions on the preparation and administration of TAKHZYRO see single-dose vial Instructions for Use.
Frequently asked questions
More about Takhzyro (lanadelumab)
- Side effects
- Drug interactions
- During pregnancy or Breastfeeding
- Patient tips
- Drug images
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: hereditary angioedema agents
- FDA approval history
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.